GU Jun,FU Qiang-qiang,LU Hong-yu,et al.Efficacy and safety of decitabine for elderly patients with acute myeloid leukemia[J].同济大学学报（医学版）,2016,37(4):93-98, 103. [点击复制]
Objective To evaluate the effectiveness and safety of decitabine for older patients with acute myeloid leukemia. Methods Randomized controlled trials(RCTs) on decitabine in treatment of acute myeloid leukemia was searched from databases of PubMed, Embase, Ovid, Cochrane Library, CNKI, VIP, WanFang Data and CBM from inception to Oct, 2015. Two reviewers independently screened literature, extracted data, and assessed methodological quality. Then meta-analysis was conducted using RevMan 5.3 software. Results A total of 4 RCTs involving 628 patients were finally included. The trial arm was given decitabine while the control arm was given other therapies. The results of meta-analysis showed that for elderly patients with acute myeloid leukemia, decitabine produced a better complete remission(CR) rate than other therapies[OR=2.44,95% CI:1.46~4.06,P=0.0006], while the partial remission(PR) rate had no statistically significant difference between two arms(P＞0.05). In terms of adverse events, the incidence of grade Ⅲ or Ⅳ febrile neutropenia in decitabine arm was significantly higher than that in other therapies(OR=1.77,95% CI:1.20~2.61,P=0.004). The incidences of grade Ⅲ or Ⅳneutropenia, grade Ⅲor Ⅳthrombocytopenia, and grade Ⅲ or Ⅳ anemia were not statistically different between two arms(P＞0.05).Conclusion Current evidence suggests that decitabine achieved a higher CR rate, with comparable hematological side effects for elderly patients with AML.
